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COMPARATIVE RESULTS 
WITH THE ST. JUDE 
MEDICAL AND MEDTRONIC 
HALL MECHANICAL VALVES 
This study compared the clinical performance of the St. Jude Medical and 
Medtronic Hall mechanical valves in isolated aortic or mitral valve replace- 
ment. From 1984 to 1993, 349 St. Jude Medical valves (aortic 237, mitral 112) 
and 465 Medtronic Hall valves (aortic 272, mitral 193) were implanted in 814 
patients at the University of Ottawa Heart Institute. The patients had similar 
preoperative characteristics. The hospital mortality rate for aortic valve 
replacement was 3.4% with the St. Jude Medical valve and 5.8% with the 
Medtronic Hall valve (p = 0.26) and the rate for mitral valve replacement was 
8.9% with the St. Jude Medical valve and 11.9% with the Medtronic Hall valve 
(t7 = 0.54). Actuarial estimates of survival and freedom from complications 
were calculated. At 5 years the actuarial probability of survival (including 
hospital deaths) for aortic valve replacement was 86% +- 3% with the St. Jude 
Medical valve and 68% - 4% with the Medtronic Hall valve (p = 0.0001) and 
for mitral valve replacement was 75% - 7% with the St. Jude Medical valve 
and 70% ± 4% with the Medtronic Hall valve (p = 0.54). The most common 
cause of late death was cardiac failure and no deaths were caused by structural 
failure. The 5-year probability of freedom from bleeding after aortic valve 
replacement was 99% ± 1% with the St. Jude Medical valve and 95% ± 2% 
with the Medtronic Hall valve (p = 0.06) and after mitral valve replacement 
99% --+ 1% with the St. Jude Medical valve and 97% - 2% with the Medtronic 
Hall valve (p = 0.37). The 5-year probability of freedom from thromboembo- 
lism after aortic valve replacement was 88% - 4% with the St. Jude Medical 
valve and 81% _ 3% with the Medtronic Hall valve (p = 0.08) and after mitral 
valve replacement was 85% +l 7% with the St. Jude Medical valve and 77% ± 
5% with the Medtronic Hall valve (/7 = 0.17). Reoperation was uncommon and 
there were no cases of  structural valve failure. The 5-year actuarial estimate of 
freedom fa'om reoperation therefore for aortic valve replacement was 99% - 
1% with the St. Jude Medical valve and 96% ± 2% with the Medtronic Hall 
valve (p = 0.09) and for mitral valve replacement was 98% ± 2% with the St. 
Jude Medical valve and 95% -+ 3% with the Medtronic Hall valve (p = 0.40). 
We concluded that the St. Jude Medical and Medtronic Hall mechanical valves 
offered similar clinical performance in isolated aortic or mitral valve replace- 
ment. (J THORAC CARDIOVASC SURG 1995;110:663-71) 
R. G. Masters, MD, A. L. Pipe, MD, V. M. Walley, MD, and W. J. Keon, MD, 
Ottawa, Ontario, Canada 
T he St. Jude Medical and Medtronic Hall mechan- ical heart valves (St. Jude Medical, Inc., St. Paul, 
Minn.; Medtronic, Inc., Minneapolis, Minn.) were 
introduced for clinical use in 1977 and 1978, respec- 
From the Departments of Surgery, Pathology, and Laboratory 
Medicine, University of Ottawa Heart Institute, Ottawa Civic 
Hospital, Ottawa, Ontario, Canada. 
Received for publication Juty 25, 1994. 
Accepted for publication Dec. 22, 1994. 
Address for reprints: Roy G. Masters, MD, University of Ottawa 
Heart Institute, Ottawa Civic Hospital, 1053 Carling Ave., 
Ottawa, Ontario, Canada K1Y-4E9. 
tively. The bileaflet construction of the former and the 
tilting-disc assembly of the latter purportedly offer 
specific hemodynamic advantages. Although contro- 
versy exists as to the relative merits of each clinically, 
there are few studies from a single center thät compare 
these two prostheses. We report a study of the relative 
clinical performances of these two mechanical valves 
in the setting of isolated aortic valve replacement 
(AVR) or mitral valve replacement (MVR). 
Copyright @ 1995 by Mosby-Year Book, Inc. 
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Patients and methods 
From May 1984 to Deeember 1993, 349 St. Jude 
Medical and 465 Medtronic Hall mechanical valves were 
implanted in 814 patients at the University of Ottawa 
Heart Institute. There were 509 single valve replacements 
in the aortic position of which 237 were done with the St. 
Jude Medical valve and 272 were done with the Medtronic 
Hall valve. There were 305 single valve replacements in 
the mitral position of which 112 were done with the St. 
Jude Medical valve and 193 were done with the Medtronic 
Hall valve. 
The choice of valve was made at the surgeon's discre- 
tion and the surgical technique and follow-up were similar 
for all patients. In general each surgeon used one brand 
throughout he study period. Operative technique in- 
cluded cardiopulmonary b pass with moderate hypother- 
mia, topical cooling with saline solution, and cold crystal- 
loid cardioplegic solution administered in the antegrade 
fashion. The implantation technique consisted of the use 
of interrupted horizontal mattress sutures reinforced with 
Teflon pledgets. Warfarin sodium administration was 
started within 72 hours after operation. During the initial 
years of the study the target prothrombin time ratio was 
1.5 to 2.0 and most recently the target International 
Normalized Ratio (INR) was set at 2.5 to 3.5. Regulation 
of anticoagulation therapy after discharge from the hos- 
pital was by the patient's family physician or cardiologist 
after initial stabilization of the therapeutic results by the 
surgeon. 
Follow-up. All patients who underwent valve replace- 
ment were registered with the Valve Clinic of the 
Ottawa Heart Institute. Survivors were evaluated annu- 
ally and the closure date for this study was March 1, 
1994. Of the 814 patients, 12% were considered lost to 
follow-up. There were 1172 patient-years of follow-up 
for the AVR group and 599 patient-years of follow-up 
for the MVR group. 
Statistieal analysis. Data are presented in strict accor- 
dance with the Guidelines for Reporting Morbidity and 
Mortality After Cardiac Valvular Operations.1 In addition 
we further defined major bleeding according to these 
Guidelines (as bleeding that caused eath, stroke, opera- 
tion, or hospitalization or that necessitated transfusion) 
and all other bleeding as minor. 
Comparisons between the preoperative eharacteris- 
tics of the patient groups were made by the X 2 test or 
Fisher's exact test where appropriate for discrete vari- 
ables and Student's t test for continuous variables. Late 
survival (ffeedom from death) and event-free probabil- 
ities were calculated by means of the life-table tech- 
nique with SPSS statistical data analysis oftware (SPSS 
Inc., Chicago, Ill.) and are reported with 95% confi- 
dence limits. Comparisons between groups were made 
with the formula 
Px- ptx 
z = x/(SE[P~]): + (SE[P,j) 2 
which is defined in Colton. 2 Results were considered 
statistically significant at the p < 0.05 level. 
Results 
Clinical characteristics. In both the AVR and 
MVR groups the average age of the patients at the 
time of implantation was similar: in the AVR group 
it was 58.5 -+ 0.9 years in patients with the St. Jude 
Medical valve and 57.8 - 0.8 years in patients with 
the Medtronic Hall valve (p = 0.31) and in the 
MVR group it was 58.2 _+ 1.2 years in patients with 
the St. Jude Medical valve and 57.9 _+ 0.9 years in 
patients with for the Medtronic Hall valve (p = 
0.49). In the AVR group the proportion of male 
patients was 70% for the St. Jude Medical valve and 
68% for the Medtronic Hall valve (p = 0.70), 
whereas in the MVR group there was a greater 
proportion of female patients in the Medtronic Hall 
valve group (67%) than in the St. Jude Medical 
valve group (56%) (p = 0.04). In the AVR group 
previous valve operations had been done in 23% of 
patients who received the St. Jude Medical valve 
and 34% of the patients who received the Medtronic 
Hall valve (p = 0.005), whereas in the MVR group 
previous operations had been done in 30% of the St. 
Jude Medical valve group and 32% of the Medtronic 
Hall valve group (p = 0.80). 
Concomitant operations were done in 22% of 
patients: in the AVR group in 27% of patients 
receiving the St. Jude Medical valve and 21% re- 
ceiving the Medtronic Hall valve (p = 0.19) and in 
the MVR group in 22% of patients receiving the 
St. Jude Medical valve and 16% receiving the 
Medtronic Hall valve (p = 0.22). Coronary artery 
bypass was the most common associated proeedure, 
being and it was done in 93% of patients with a 
similar distribution among all four groups. 
Before operation most patients were in New York 
Heart Association functional class I I I  or IV. For 
AVR this included 60% and 66% (p = 0.17) and for 
MVR 68% and 68% (p = 0.99) of patients with the 
St. Jude Medical valve and Medtronic Hall valve, 
respectively. After operation, however, few were in 
class I I I  or IV. For AVR this included 7% and 8% 
(p = 0.81) and for MVR 9% and 9% (p = 0.84) of 
patients with the St. Jude Medical valve and 
Medtronic Hall valve, respectively (Table I). 
Hospital mortality. Among the patients having 
AVR there were 8 hospital deaths in patients with 
the St. Jude Medical valve (3.4%) and 16 hospital 
deaths in patients with the Medtronic Hall valve 
(5.8%) (p = 0.26). In the MVR group there were 10 
deaths in patients with the St. Jude Medical valve 
(8.9%) and 23 in patients with the Medtronic Hall 
valve (11.9%) (p = 0.53). In the AVR group a 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Nurnber 3 
Masters et al. 665 
Table I. Preoperative characteristics of the patient groups 
AVR MVR 
St. Jude Medical Medtronic Hall p Value St. Jude Medical Medtronic Hall p Value 
No. of patients 237 272 
Mean age (yr) 58.5 _+ 0.9 57.8 + 0.8 
Sex ratio (male/female) 165/72 184/88 
Previous valve operation 54 (23%) 93 (34%) 
Concornitant operation 63 (27%) 58 (21%) 
NYHA functional class III/IV 142 (60%) 180 (66%) 
112 193 
0.31 58.2 -+ 1.2 57.9 -+ 0.9 0.49 
0.70 49/63 63/130 0.04 
0.005 34 (32%) 61 (32%) 0.80 
0.19 25 (22%) 31 (16%) 0.22 
0.17 76 (68%) 131 (68%) 0.99 
NYHA, New York Heart Association. 
previous operation did not affect hospital survival. 
Patients having a first operation had a mortality rate 
of 3.6% cornpared with 7.4% for those having 
previous operations (p = 0.10). Similarly in the 
MVR group gender did not influence arly survival. 
Male patients had a mortality rate of 13.4% com- 
pared with 8.6% for female patients (p = 0.26). No 
deaths in eit:her group were directly attributable to 
prosthetic valve failure. Autopsy was done in 61% of 
deaths in patients who received a St. Jude Medical 
valve and 67% of deaths in patients who received a
Medtronic Hall valve. Major causes of death in- 
cluded myocardial dysfunction (St. Jude Medical 
valve 8, 44%; Medtronic Hall valve 15, 38%), bleed- 
ing (St. Jude Medical valve 1, 6%; Medtronic Hall 
valve 7, 18%), multiorgan failure (St. Jude Medical 
valve 3, 17%; Medtronic Hall valve 3, 8%), sudden 
death (arrh~hmia) (St. Jude Medical valve 0; 
Medtronic Hall valve 4, 10%), and stroke (St. Jude 
Medical valve 0; Medtronic Hall valve 2, 5%). In 
addition two patients (11%) having MVR with the 
St. Jude Medical valve died primarily of technical 
problems at the time of operation, including one 
patient with left ventricular rupture and one with 
atrioventricular disruption. Technical problems 
caused eath in six patients (15%) who received the 
Medtronic Hall valve including left ventricle-to- 
right atrium fistula in three patients having MVR, 
aortic dissecfion in two patients having AVR, and 
ventricular septal defect in one patient having AVR. 
Late survival. There were a total of 51 late deaths 
recorded after AVR: 12 in patients receiving the St. 
Jude Medical valve and 39 in patients receiving the 
Medtronic Hall valve. Cardiac failure, not related to 
prosthetic valve dysfunction, was the most common 
cause of these late deaths, accounting for 33% and 
41%, respectively, of these late deaths. Valve-re- 
lated deaths accounted for three late deaths in the 
group having AVR with the St. Jude Medical valve 
and six late deaths in the group having AVR with 
the Medtronic Hall valve. These included death 
from thromboembolism, endocarditis, or hemor- 
rhage. The actuarial probability of survival to 5 years 
after AVR with the St. Jude Medical valve was 
86% __ 3% and 68% _+ 4% after AVR with the 
Medtronic Hall valve (p = 0.0001) (Fig. 1). 
After MVR there were a total of 28 late deaths, 8
in patients with the St. Jude Medical valve and 20 in 
patients with the Medtronic Hall valve. Deaths as a 
result of cardiac failure accounted for 25% and 
50%, respectively, of these late deaths. There was 1 
valve-related late death in the former group and 2 in 
the latter. Therefore the actuarial probability of 
survival to 5 years after MVR with the St. Jude 
Medical valve was 75% _+ 7% and 70% _+ 4% with 
the Medtronic Hall valve (p = 0.54) (Fig. 2). 
Morbidity. Bleeding was identified in 5 patients 
after AVR with the St. Jude Medical valve and in 19 
patients after AVR with the Medtronic Hall valve. 
Major bleeding after AVR with the St. Jude Medical 
valve was seen in 1 patient who died and in 8 after 
AVR with the Medtronic Hall valve, 2 of whom 
died. The actuarial freedom from major bleeding at 
5 years therefore for AVR was 99% _+ 1% with the 
St. Jude Medical valve and 95% _ 2% with the 
Medtronic Hall valve (p = 0.06). Bleeding after 
MVR was seen in 3 patients with the St. Jude 
Medical valve and 9 patients with the Medtronic 
Hall valve. Major bleeding was seen in 1 of the 
former and 4 of the latter patients, with no deaths. 
The 5-year actuarial freedom from major bleeding 
after MVR therefore was 99% _+ 1% with the St. 
Jude Medical valve and 97% + 2% with the 
Medtronic Hall valve (p = 0.37). Thromboembolism 
was noted in 13 patients (15 events) after AVR with 
the St. Jude Medical valve and in 34 (42 events) 
after AVR with the Medtronic Hall valve. After 
AVR with the St. Jude Medical valve there were 14 
neurologic events, consisting of a transient ischemic 
attack (TIA) in 10 patients (12 events) and a stroke 
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Fig. 1. Actuarial survival (freedom from death): AVR. SJM-AVR, AVR with the St. Jude Medical valve; 
MH-AVR, AVR with the Medtronic Hall valve. 
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Fig. 2. Actuarial survivat (freedom from death): MVR. SJM-MV& MVR with the St. Jude Medical valve; 
MH-MVR, MVR with the Medtronic Hall valve. 
(CVA) in 2 patients. Peripheral embolism occurred 
in 1 patient. There were no deaths as a result of 
these complications in this group. After AVR with 
the Medtronic Hall valve 21 patients had TIA (29 
events) and 12 a stroke (12 events). One patient had 
a myocardial infarction thought to be embolic in 
origin. Death occurred in 2 of these patients as a 
result of stroke. The 5-year actuarial freedom from 
thromboembolism after AVR was 88% + 4% with 
the St. Jude Medical valve and 81% + 3% with the 
Medtronic Hall valve (p = 0.08) (Fig. 3). Of the 
patients having AVR with the St. Jude Medical 
valve who had emboli 78% (10) were in sinus 
rhythm, whereas 85% (29) of the patients having 
AVR with the Medtronic Hall valve were in sinus 
rhythm. 
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Fig. 3. Actuarial freedom from thromboembolism: AVR. SJM-AVR, AVR with the St. Jude Medical valve; 
MH-A VR, AVR with the Medtronic Hall valve. 
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Fig. 4. Actuarial freedom from thromboembolism: MVR. SJM-MVR, MVR with the St. Jude Medical 
valve; MH-MVR, MVR with the Medtronic Hall valve. 
Thromboembolism was seen after MVR in 6 
patients (7 events) with the St. Jude Medical valve 
and 22 patients (32 events) with the Medtronic Hall 
valve. In the former this consisted of TIA alone in 3 
patients (3 events) and a CVA in 2 patients (2 
events). One patient had a TIA followed by a CVA. 
There was 1 death that occurred after a stroke. After 
MVR with the Medtronic Hall valve 15 patients had 
TIA alone (20 events) and 3 patients had CVA 
alone (5 events). Three patients had TIA followed 
by CVA and 1 patient had a peripheral embolism. 
There were no deaths in this group caused by 
thromboembolism. The 5-year actuarial freedom 
from thromboembolism after MVR therefore was 
85% +- 7% with the St. Jude Medical valve and 
77% _+ 5% with the Medtronic Hall valve (p = 0.17) 
(Fig. 4). Of the patients having MVR with the St. 
Jude Medical valve who had emboli norle (0%) were 
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Fig. 5. Actuarial freedom from reoperation: AVR. SJM-AVR, AVR with the St. Jude Medical valve; 
MH-A VR, AVR with the Medtronic Hall valve. 
in sinus rhythm, whereas of the patients having 
MVR with the Medtronic Hall valve who had em- 
boli only 36% (8) were in sinus rhythm. 
Endocarditis was identified in 13 patients after 
AVR: 4 in the St. Jude Medical valve group and 9 in 
the Medtronic Hall valve group. There were 2 
deaths in each group as a result of this complication. 
The 5-year actuarial freedom from endocarditis 
after AVR was 97% _+ 1% with the St. Jude Medical 
valve and 94% _+ 2% with the Medtronic Hall valve 
(p = 0.09). Endocarditis was identified in 6 patients 
after MVR: 2 in the St. Jude Medical valve group 
and 4 in the Medtronic Hall valve group. There were 
2 deaths as a result of this complication, both in the 
latter group. At 5 years the actuarial freedom from 
endocarditis after MVR was 97% _+ 2% with the St. 
Jude Medical valve and 96% _+ 2% with the 
Medtronic Hall valve (p = 0.72). 
Reoperation after discharge was uncommon with 
either valve in either position. There were no cases 
of structural dysfunction i  this study. Reoperation 
was required for two patients having AVR with the 
St. Jude Medical valve and seven patients having 
AVR with the Medtronic Hall valve. Both patients 
in the former group required reoperation because of 
prosthetic valve endocarditis and there was one 
resultant death. In the latter group reoperation was 
required because of endocarditis in three patients, 
nonstructural failure (paravalvular leaks) in two, 
and iatrogenic ventricular septal defect in one case 
and in one patient where there was thought o be a 
high transvalvular gradient. There was only one 
death among these patients, and it occurred in the 
patient with a ventricular septal defect in whom 
multiorgan failure developed after-operation. The 
5-year actuarial freedom from reoperation in pa- 
tients having AVR was 99% _+ 1% with the St. Jude 
Medical valve and 96% + 2% with the Medtronic 
Hall valve (p = 0.09) (Fig. 5). 
Reoperation was required in one patient receiv- 
ing MVR with the St. Jude Medical valve and in six 
patients receiving MVR with the Medtronic Hall 
valve. The former patient required reoperation be- 
cause of endocarditis and survived. In the latter 
group three patients required reoperation because 
of endocarditis, one because of nonstructural fail- 
ure, and one because of recurrent TIAs and one 
required transplantation because of terminal heart 
failure. Death occurred in two of the patients who 
had reoperation because of endocarditis. The 5-year 
actuarial freedom from reoperation after MVR 
therefore was 98% + 2% with the St. Jude Medical 
valve and 95% _+ 3% with the Medtronic Hall valve 
(p = 0.40) (Fig. 6). 
Discussion 
The St. Jude Medical and the Medtronic Hall 
prosthetic valves remain the most widely used me- 
chanical valves in North America. Although a num- 
ber of authors have reported their experience with 
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one of these valves, there are few smdies from a 
single center that compare the relative efficacy of 
both. This may be important because referral pat- 
terns may vary from one institution to another, as 
may operative techniques and postoperative man- 
agement, which orten makes comparisons difficult. 
Though the hospital mortality reported here was 
lower for AVR with the St. Jude Medical valve this 
difference did not reach statistical significance. Be- 
lore operation both groups of patients having AVR 
were similar though there was a greater proportion 
of reoperations in the group having AVR with the 
Medtronic Hall valve. In this study previous opera- 
tion was not a risk factor for hospital mortality after 
AVR. Factors that have previously been noted as 
independent determinants of survival for AVR have 
included the urgency of operation, the presence of 
endocarditis, previous valve operation, concurrent 
coronary: artery disease, and patient age)'4 Previ- 
ously reported hospital mortality rates for AVR with 
the St. Jude Medical valve have been 2.4%, 4 3.2%, 5 
3.6%, 6 5i2%, 7 5.8%, 8 and 7%. 9 For AVR with the 
Medtronic Hall valve early mortality rates of 1.7%, 1° 
3.8%, 11 4.2%, 12 and 9.3% 13 have been reported. The 
hospital mortality rate r ported here was lower for 
MVR with the St. Jude Medical valve but again this 
did not }each statistical significance. In this study 
there was a greater proportion of female patients in 
the group having MVR with the Medtronic Hall 
valve; however, this was not a risk factor for early 
death. Independent determinants of survival for 
MVR from previous tudies haved include urgency, 
endocarditis, coronary disease, age, and ventricular 
function.3, 4 Gender, however, was also not a risk 
factor in these studies. Operative mortality rates of 
4.3%, 3 4.7%, 6 7.4%, • 8%, 9 9.9%, 5 and 11.9% 7have 
been reported for MVR with the St. Jude Medical 
valve and 7.5%, 11 7.8%, 13 8.4%, 10 and 13.1% 12 for 
MVR with the Medtronic Hall valve. 
Anthunes, 14 in 1990, reported the results of a 
prospective randomized comparison of the St. Jude 
Medical and Medtronic Hall valves. This study of 
isolated MVR and AVR did not include patients 
who had previous valvular operations and it grouped 
the aortic and mitral valve results together. The 
hospital mortality rate in that study was 3.2% (3 
patients) for the 89 patients receiving the St. Jude 
Medical valve and 5.7% (5 patients) for the 80 
patients receiving the Medtronic Hall valve. Simi- 
larly a 1992 prospective randomized study by Fiore 
and associates 15compared the results of MVR with 
the St. Jude Medical and Medtronic Hall valves. The 
hospital mortality rate in that study, however, was 
higher for the 55 patients receiving a St. Jude 
Medical valve than for the 47 patients receiving a 
Medtronic Hall valve at 14.5% (8 patients) and 
10.6% (5 patients), respectively. The early survival 
differences noted in both of these studies, however, 
did not reach statistical significance at the 0.05 level 
possibly because of the study sizes. 
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We have detected a late survival advantage with 
the St. Jude Medical valve for isolated AVR or 
MVR at 5 years; this difference only reaches tatis- 
tical significance with the former. Beyond 5 years 
the number of patients at risk in this study is small, 
which makes comparisons i appropriate. Actuarial 
5-year estimates of survival of 71% _ 3%, 7 78%, 4 
78% -- 4%, s and 96% 16 for AVR with the St. Jude 
Medical valve and 70% _+ 6%, 12 72% _+ 5%, 13 
82%, 11 and 89% l° for AVR with the Medtronic Hall 
valve have previously been reported. Survival esti- 
mates of 59% + 4%, 7 64% _+ 9%, 5 78%, 4 and 88% 16 
for MVR with the St. Jude Medical valve and 
67% _+ 6%, 12 72% _+ 5%, 13 74%, 11 and 79% l° for 
MVR with the Medtronic Hall valve have also been 
reported. In the study by Fiore and associates is the 
3-year survival was lower for MVR with the St. Jude 
Medical valve (79% _+ 5%) than for MVR with the 
Medtronic Hall valve (87% _+ 5%). Anthunes 14 also 
found a lower 5-year survival with St. Jude Medical 
valves (74% _ 6%) than Medtronic Hall valves 
(88% _+ 5%) despite the higher hospital mortality 
rate with the latter. Late survival is dependent on 
many factors related to the individual patients' 
disease and to the complications of the prostheses. 
Most deaths in our study were a result of cardiac 
failure and were not related to prosthetic valve 
dysfunction or failure or its attendant complications. 
At 5 years we could not detect large differences 
between these two valves in freedom from compli- 
cations. In all cases, however, the actuarial estimate 
was higher with the St. Jude Medical valve for either 
AVR or MVR, though the differences were not 
significant statistically. The actuarial freedom from 
thromboembolism was higher for the St. Jude Med- 
ical valve in both the aortic and mitral positions in 
this study. The 5-year freedom from thromboembo- 
lism after AVR with the St. Jude Medical valve has 
previously been reported at 88% _ 3%, 7 92%, 4 
92% _+ 4%, 5 and 97% _+ 6% 8 and after AVR with 
the Medtronic Hall valve at 82% _+ 4%, 13 92% _ 
3%, 12 and 95%. I° After MVR with the St. Jude 
Medical valve 5-year actuarial estimates have been 
reported at 85%, 4 89% _ 5%, s 92% _+ 2%7 and 
99% + 1% 8 and after MVR with the Medtronic 
Hall valve at 85% _+ 8%, 12 89% _+ 3%, 13 and 94%. l° 
Clearly the occurrence of thromboemboli and 
bleeding after heart valve replacement is related to 
the level of anticoagulation, which varies among 
studies. In our study the target levels of anticoagu- 
lation were the same for both the St. Jude Medical 
and Medtronic Hall valves. However, beyond the 
initial few weeks required for stabilization, control 
of anticoagulation was not centralized. Further, we 
do not have complete records of the actual evel of 
prothrombin time or INR at the time of thrombo- 
embolism. Current recommendations are for a tar- 
get INR of 2.5 to 3.5 for all mechanical valves. 17 The 
comparative study by Anthunes 14 did not detect a 
statistically significant difference in freedom from 
thromboembolism at 5 years between the St. Jude 
Medical valve (92% + 4%) and the Medtronic Hall 
valve (89% _+ 4%) with a prothrombin dex of 35% 
to 45%. Similarly although there was an apparent 
advantage with the St. Jude Medical valve in the rate 
of thromboembolism at 3 years in the study of Fiore 
and associates is (98% _+ 2% versus 88% _ 6%) in 
which a prothrombin ratio of 1.5 was used this did 
not reach statistical significance. 
Serious bleeding was uncommon i our study with 
less bleeding noted with St. Jude Medical valves in 
both aortic and mitral positions. Previous studies 
have reported the freedom from hemorrhage after 
AVR with the St. Jude Medical valve to be 89% + 
2%, 7 94%, 4 and 98% _+ 2% » and that after AVR 
with the Medtronic Hall valve to be 100%. 12 After 
MVR with the St. Jude Medical valve freedom from 
hemorrhage has been reported as 87%, 4 97% _+ 
3%, 5 and 92% + 2% 7 and after MVR with the 
Medtronic Hall valve 100%. 12 One study grouped 
AVR and MVR with the Medtronic Hall valve and 
reported a combined 5-year estimate of 98% _+ 
1%. 13 Anthunes 14 did not find any cases of serious 
bleeding with either valve in either position, whereas 
Fiore and associates 15 did not detect any large 
differences in bleeding between MVR with the St. 
Jude Medical valve and the Medtronic Hall valve 
(91% _+ 5% versus 94% _+ 4%) with a target 
prothrombin ratio of 1.5. 
As in most previous reports we noted a low rate of 
endocarditis with little difference between the two 
valves. Arom and colleagues s reported a 6-year 
actuarial freedom from endocarditis of 99% _+ 2% 
for AVR with the St. Jude Medical valve and 99% _+ 
1% for MVR with the Medtronic Hall valve. Simi- 
larly Keenan and associates 12reported 5-year esti- 
mates of 96% _ 2% for AVR with the Medtronic Hall 
valve and 99% _+ 2% for MVR with the Medtronic 
Hall valve. Reoperation i our short-term follow-up 
study was also uncommon, which attests to the similar 
durability of these valves. Of note, there were no cases 
of structural failure in our series. 
In summary, the results obtained from this study 
indicate that the St. Jude Medical and the Medtronic 
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Hall prostheses offer similar excellent clinical per- 
formance for both AVR and MVR. Although our 
results suggest an advantage in favor of the St. Jude 
Medical valve both in terms of survival and compli- 
cations these differences await further clarification 
with more patients followed up for a longer period 
of time. 
We wish to acknowledge the capable assistance of Ms. 
Mary Thompson, Ms. Sharon Finlay, Mr. Daniel Duguay, 
Mr. Bill Stinson, and Research Systems Associates, Ot- 
tawa. 
REFERENCES 
1. Edmunds LH, Clark RE, Cohn LH, Miller C, Weise1 
RD. Guidelines for reporting morbidity and mortality 
aftèr cardiac valvular operations. Ann Thorac Surg 
1988;46:257-9. 
2. Colton T. Longitudinal studies and use of life tables. 
In: Colton T. Statistics in medicine. Ist ed. Boston: 
Little Brown, 1974:237-50. 
3. Christakis GT, Weisel RD, David TE, Salerno TA, 
Ivanov J. Predictors of operative survival after valve 
replacement. Circulation 1988;78(Suppl):I25-34. 
4. Ibrahim M, Cleland J, O'Kane H, Gladstone D, 
Mulholland C, Craig B. The St. Jude Medical pros- 
thesis: a thirteen-year experience. J THORAC CARDIO- 
VASC SURG 1994;108:221-30. 
5. Arom KV, Nicoloff DM, Kersten TE, et al. Ten years' 
experience with the St. Jude Medicäl valve prosthesis. 
Ann Thorac Surg 1989;47:831-7. 
6. Baudet EM, Oca CC, Roques XF, et al. A 51/2 year 
experißnce with the St. Jude Medical cardiac valve 
prosthesis. J THORAC CARDIOVASC SURG 1985;90:137- 
44. 
7. Czer LSC, Chaux A, Matloff JM, et al. Ten year 
experience with the St. Jude Medical valve for pri- 
mary valve replacement. J THORAC CARDIOVASC SURG 
1990;100:44-55. 
8. Duncan JM, Cooley DA, Reul G, et al. Durability and 
low thrombogenicity of the St. Jude Medical valve at 
5 years follow-up. Ann Thorac Surg 1986;42:500-5. 
9. DiSesa VJ, Collins JJ, Cohn LH. Hematological com- 
plications of the St. Jude valve and reduced dose 
Coumadin. Ann Thorac Surg 1989;48:280-3. 
10. Vallejo JL, Gonzales-Santos JM, Albertos J, et al. 
Eight years' experience with the Medtronic Hall valve 
prosthesis. Ann Thorac Surg 1990;50:429-36. 
11. Nitter-Hauge S, Abdelnoor M. Ten-year experience 
with the Medtronic Hall valvular prosthesis. Circula- 
tion 1989;80(Suppl):I43-8. 
12. Keenan RJ, Armitage JM, Trento A, et al. Clinical 
experience with the Medtronic Hall valve prosthesis. 
Ann Thorac Surg 1990;50:748-53. 
13. Anthunes MJ, Wessels A, Sadowski RG, et al. 
Medtronic Hall replacement in a third-world popula- 
tion group. J THORAC CARDIOVASC SURG 1988;95:980- 
93. 
14. Anthunes MJ. Clinical performance of St. Jude and 
Medtronic Hall prostheses: a randomized compara- 
tive study. Ann Thorac Surg 1990;50:743-7. 
15. Fiore AC, Naunheim KS, D'Orazio S, et al. Mitral 
valve replacement: randomized trial of St. Jude and 
Medtronic Hall prostheses. Ann Thorac Surg 1992;54: 
68-73. 
16. Burckhardt D, Striebel D, Vogt S, et al. Heart valve 
replacement with St. Jude Medical prosthesis: long- 
term experience in 743 patients in Switzerland. Cir- 
culation 1988;78(Suppl):I18-24. 
17. Stein PD, Alpert JS, Copeland J, et al. Antithrom- 
botic therapy in patients with mechanical nd biologic 
prosthetic heart valves. Chest 1992;102:445-55. 
